Printer Friendly

PHYTOPHARMACEUTICALS INC. NAMES WILLIAM A. HASLER TO BOARD OF DIRECTORS

 SAN CARLOS, Calif., Nov. 3 /PRNewswire/ -- PHYTOpharmaceuticals Inc. (PPI), a subsidiary of ESCAgenetics Corp. (AMEX: ESN), announced today that William A. Hasler has been elected as a member of its board of directors. PPI is a plant-based pharmaceutical company that discovers and develops novel therapeutic compounds using a global plant resource network and proprietary plant cell tissue culture technology.
 Hasler is dean of the Haas School of Business at the University of California at Berkeley, and is a former vice chairman and director of KPMG Peat Marwick. He also serves as a member of the board of directors of ESCAgenetics, as a member of the board of governors of the Pacific Stock Exchange and as treasurer of the Pacific Basin Economic Council.
 "Dean Hasler joins us at an exciting juncture with our discovery of novel taxoids that are related to taxol and the execution of exclusive collaborative agreements that will provide thousands of certified plant extracts, collected globally, for use in our drug discovery program," said Dr. Thomas M. Glenn, president and chief operating officer of PHYTOpharmaceuticals Inc. "We are fortunate to benefit from Mr. Hasler's extensive international business experience and look forward to receiving his contributions as a member of our board of directors."
 "PHYTOpharmaceuticals is well positioned to become a high-value drug discovery company and our strong organizational structure, including the addition of Dean Hasler to our board, enhances our ability to achieve our business goals," said PPI's chief executive officer and chairman, Douglas J. MacMaster Jr.
 PHYTOpharmaceuticals is a plant-based drug discovery company that combines biotechnology and biodiversity for the discovery, development and commercialization of novel human therapeutics, based upon a comprehensive plant-sourcing, proprietary plant cell culture technology and a pharmacological screening program. PPI's resources include plant collection and certified extract production laboratories in China, Brazil and Thailand, some of the most biodiverse regions of the world.
 ESCAgenetics Corp. is a publicly traded company that develops and produces high-value, plant-derived products.
 -0- 11/3/93
 /CONTACT: Dr. Thomas M. Glenn, president & chief operating officer of PHYTOpharmaceuticals, 415-595-5335; or William J. Koenig, executive vice president of PHYTOpharmaceuticals, 415-595-5335/
 (ESN)


CO: PHYTOpharmaceuticals; ESCAgenetics Corp. ST: California IN: MTC SU: PER

LH-TM -- SF002 -- 9943 11/03/93 08:01 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 3, 1993
Words:370
Previous Article:CARR GOTTSTEIN FOODS CO. ANNOUNCES THIRD QUARTER RESULTS
Next Article:NASSCO AND THE U.S. NAVY CELEBRATE THE LAUNCHING OF THE FAST COMBAT SUPPORT SHIP 'U.S.S. ARCTIC'
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters